Literature DB >> 20702406

Regulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-{alpha}, IL-6, and IL-1{beta}.

Lei Diao1, Na Li, Timothy G Brayman, Kathy J Hotz, Yurong Lai.   

Abstract

In the present study MRP2/ABCC2 and BSEP/ABCB11 expression were investigated in sandwich cultured (SC) human and rat hepatocytes exposed to the proinflammatory cytokines. The investigation was also done in lipopolysaccharide (LPS)-treated rats. In SC human hepatocytes, both absolute protein and mRNA levels of MRP2/ABCC2 were significantly down-regulated by TNF-α, IL-6, or IL-1β. In contrast to mRNA decrease, which was observed for BSEP/ABCB11, the protein amount was significantly increased by IL-6 or IL-1β. A discrepancy between the change in BSEP/ABCB11 mRNA and protein levels was encountered in SC human hepatocytes treated with proinflammatory cytokines. In SC rat hepatocytes, Mrp2/Abcc2 mRNA was down-regulated by TNF-α and IL-6, whereas the protein level was decreased by all three cytokines. Down-regulations of both Bsep/Abcb11 mRNA and protein levels were found in SC rat hepatocytes exposed to TNF-α or IL-1β. Administration of LPS triggered the release of the proinflammatory cytokines and caused the decrease of Mrp2/Abcc2 and Bsep/Abcb11 protein in liver at 24 h post-treatment; however, the Mrp2 and Bsep protein levels rebounded at 48 h post-LPS treatment. In total, our results indicate that proinflammatory cytokines regulate the expression of MRP2/Mrp2 and BSEP/Bsep and for the first time demonstrate the differential effects on BSEP/Bsep expression between SC human and rat hepatocytes. Furthermore, the agreement between transporter regulation in vitro in SC rat hepatocytes and in vivo in LPS-treated rats during the acute response phase demonstrates the utility of in vitro SC hepatocyte models for predicting in vivo effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20702406      PMCID: PMC2951192          DOI: 10.1074/jbc.M110.107805

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate.

Authors:  C Funk; M Pantze; L Jehle; C Ponelle; G Scheuermann; M Lazendic; R Gasser
Journal:  Toxicology       Date:  2001-10-05       Impact factor: 4.221

2.  Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes.

Authors:  Daniel A J Bow; Jennifer L Perry; David S Miller; John B Pritchard; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2007-10-22       Impact factor: 3.922

3.  LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process.

Authors:  Marieke G L Elferink; Peter Olinga; Annelies L Draaisma; Marjolijn T Merema; Klaas Nico Faber; Maarten J H Slooff; Dirk K F Meijer; Geny M M Groothuis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-06-17       Impact factor: 4.052

4.  Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer.

Authors:  Edward T Morgan; Kerry B Goralski; Micheline Piquette-Miller; Kenneth W Renton; Graham R Robertson; Madhusudana R Chaluvadi; Kellie A Charles; Stephen J Clarke; Marina Kacevska; Christopher Liddle; Terrilyn A Richardson; Rohini Sharma; Christopher J Sinal
Journal:  Drug Metab Dispos       Date:  2008-02       Impact factor: 3.922

5.  Redistribution of canalicular organic anion transport activity in isolated and cultured rat hepatocytes.

Authors:  H Roelofsen; C T Bakker; B Schoemaker; M Heijn; P L Jansen; R P Elferink
Journal:  Hepatology       Date:  1995-06       Impact factor: 17.425

6.  Obstructive cholestasis induces TNF-alpha- and IL-1 -mediated periportal downregulation of Bsep and zonal regulation of Ntcp, Oatp1a4, and Oatp1b2.

Authors:  Markus G Donner; Stephanie Schumacher; Ulrich Warskulat; Jane Heinemann; Dieter Häussinger
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-10-04       Impact factor: 4.052

7.  Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response.

Authors:  Anne P Beigneux; Arthur H Moser; Judy K Shigenaga; Carl Grunfeld; Kenneth R Feingold
Journal:  Biochem Biophys Res Commun       Date:  2002-04-26       Impact factor: 3.575

8.  LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species.

Authors:  Na Li; Joe Palandra; Olga V Nemirovskiy; Yurong Lai
Journal:  Anal Chem       Date:  2009-03-15       Impact factor: 6.986

Review 9.  Mechanisms of cytochrome P450 regulation by inflammatory mediators.

Authors:  Edward T Morgan; Tong Li-Masters; Po-Yung Cheng
Journal:  Toxicology       Date:  2002-12-27       Impact factor: 4.221

Review 10.  Human hepatocytes in primary culture: the choice to investigate drug metabolism in man.

Authors:  M J Gómez-Lechón; M T Donato; J V Castell; R Jover
Journal:  Curr Drug Metab       Date:  2004-10       Impact factor: 3.731

View more
  14 in total

1.  Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.

Authors:  Amélie Moreau; Marc Le Vée; Elodie Jouan; Claire Denizot; Yannick Parmentier; Olivier Fardel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

2.  Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids.

Authors:  Lirui Wang; Phillipp Hartmann; Michael Haimerl; Sai P Bathena; Christopher Sjöwall; Sven Almer; Yazen Alnouti; Alan F Hofmann; Bernd Schnabl
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

3.  Jaundice in a patient treated with Anakinra in a context of Covid-19.

Authors:  H Tarhini; M Husain; N Poey; S Lariven; F-X Lescure; Y Yazdanpanah; A Gervais
Journal:  Infect Dis Now       Date:  2020-09-30

Review 4.  Effect of Liver Disease on Hepatic Transporter Expression and Function.

Authors:  Nilay Thakkar; Jason R Slizgi; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2017-04-30       Impact factor: 3.534

5.  Yinzhihuang attenuates ANIT-induced intrahepatic cholestasis in rats through upregulation of Mrp2 and Bsep expressions.

Authors:  Qiao-Qun Ou; Xin-Hua Qian; Ding-You Li; You-Xiang Zhang; Xia-Nan Pei; Jin-Wen Chen; Li Yu
Journal:  Pediatr Res       Date:  2015-12-08       Impact factor: 3.756

6.  Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients.

Authors:  Silke Leonhardt; Wilfried Veltzke-Schlieker; Andreas Adler; Eckart Schott; Roland Hetzer; Walter Schaffartzik; Michael Tryba; Peter Neuhaus; Daniel Seehofer
Journal:  Crit Care       Date:  2015-03-31       Impact factor: 9.097

7.  Maternal protein restriction induces alterations in hepatic tumor necrosis factor-α/CYP7A1 signaling and disorders regulation of cholesterol metabolism in the adult rat offspring.

Authors:  Xiaomei Liu; Ying Qi; Baoling Tian; Dong Chen; Hong Gao; Chunyan Xi; Yanlin Xing; Zhengwei Yuan
Journal:  J Clin Biochem Nutr       Date:  2014-05-13       Impact factor: 3.114

Review 8.  Clinical application of transcriptional activators of bile salt transporters.

Authors:  Anna Baghdasaryan; Peter Chiba; Michael Trauner
Journal:  Mol Aspects Med       Date:  2013-12-12

9.  Successful mouse hepatocyte culture with sandwich collagen gel formation.

Authors:  Hyun Jung Choi; Dongho Choi
Journal:  J Korean Surg Soc       Date:  2013-03-26

10.  Advances in sepsis-associated liver dysfunction.

Authors:  Dawei Wang; Yimei Yin; Yongming Yao
Journal:  Burns Trauma       Date:  2014-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.